NF-κB dysregulation in multiple myeloma

Geoffrey M. Matthews; Ricardo de Matos Simoes; Eugen Dhimolea; Michal Sheffer; Sara Gandolfi; Olga Dashevsky; Jeffrey D. Sorrell; Constantine S. Mitsiades

doi:10.1016/j.semcancer.2016.08.005

NF-κB dysregulation in multiple myeloma

Geoffrey M. Matthews, Ricardo de Matos Simoes, Eugen Dhimolea, Michal Sheffer, Sara Gandolfi, Olga Dashevsky, Jeffrey D. Sorrell, Constantine S. Mitsiades

Research output: Contribution to journal › Review article › peer-review

29 Scopus citations

Abstract

The nuclear factor-κB (NF-κB) transcription factor family plays critical roles in the pathophysiology of hematologic neoplasias, including multiple myeloma. The current review examines the roles that this transcription factor system plays in multiple myeloma cells and the nonmalignant accessory cells of the local microenvironment; as well as the evidence indicating that a large proportion of myeloma patients harbor genomic lesions which perturb diverse genes regulating the activity of NF-κB. This article also discusses the therapeutic targeting of the NF-κB pathway using proteasome inhibitors, a pharmacological class that has become a cornerstone in the therapeutic management of myeloma; and reviews some of the future challenges and opportunities for NF-κB-related research in myeloma.

Original language	English (US)
Pages (from-to)	68-76
Number of pages	9
Journal	Seminars in Cancer Biology
Volume	39
DOIs	https://doi.org/10.1016/j.semcancer.2016.08.005
State	Published - Aug 1 2016
Externally published	Yes

Keywords

Microenvironment
Myeloma
NF-kappaB
Proteasome inhibitors
Stromal cells

ASJC Scopus subject areas

Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.semcancer.2016.08.005

Cite this

@article{0fa1d33fa8754e62b325ef55fccc219c,

title = "NF-κB dysregulation in multiple myeloma",

abstract = "The nuclear factor-κB (NF-κB) transcription factor family plays critical roles in the pathophysiology of hematologic neoplasias, including multiple myeloma. The current review examines the roles that this transcription factor system plays in multiple myeloma cells and the nonmalignant accessory cells of the local microenvironment; as well as the evidence indicating that a large proportion of myeloma patients harbor genomic lesions which perturb diverse genes regulating the activity of NF-κB. This article also discusses the therapeutic targeting of the NF-κB pathway using proteasome inhibitors, a pharmacological class that has become a cornerstone in the therapeutic management of myeloma; and reviews some of the future challenges and opportunities for NF-κB-related research in myeloma.",

keywords = "Microenvironment, Myeloma, NF-kappaB, Proteasome inhibitors, Stromal cells",

author = "Matthews, {Geoffrey M.} and {de Matos Simoes}, Ricardo and Eugen Dhimolea and Michal Sheffer and Sara Gandolfi and Olga Dashevsky and Sorrell, {Jeffrey D.} and Mitsiades, {Constantine S.}",

note = "Funding Information: The research studies of CSM have been supported by Grants R01 CA127435, R01 CA179483 and R01 CA196664 from the National Institutes of Health , the Shawna Ashlee Corman Investigatorship in Multiple Myeloma Research, the de Gunzburg Myeloma Research Fund, the Cobb Family Myeloma Research Fund, the Chambers Family Advanced Myeloma Research Fund, the Leukemia and Lymphoma Society Translational Research Program and Quest for Cure Program, the Multiple Myeloma Research Foundation and the RJ Corman Multiple Myeloma Research Fund. CSM and ED are also supported by the Claudia Adams Barr Program in Cancer Research. GMM has been supported by the American Australian Association and the International Myeloma Foundation. MS is supported by the Human Frontier Science Program. Publisher Copyright: {\textcopyright} 2016",

year = "2016",

month = aug,

day = "1",

doi = "10.1016/j.semcancer.2016.08.005",

language = "English (US)",

volume = "39",

pages = "68--76",

journal = "Seminars in Cancer Biology",

issn = "1044-579X",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - NF-κB dysregulation in multiple myeloma

AU - Matthews, Geoffrey M.

AU - de Matos Simoes, Ricardo

AU - Dhimolea, Eugen

AU - Sheffer, Michal

AU - Gandolfi, Sara

AU - Dashevsky, Olga

AU - Sorrell, Jeffrey D.

AU - Mitsiades, Constantine S.

N1 - Funding Information: The research studies of CSM have been supported by Grants R01 CA127435, R01 CA179483 and R01 CA196664 from the National Institutes of Health , the Shawna Ashlee Corman Investigatorship in Multiple Myeloma Research, the de Gunzburg Myeloma Research Fund, the Cobb Family Myeloma Research Fund, the Chambers Family Advanced Myeloma Research Fund, the Leukemia and Lymphoma Society Translational Research Program and Quest for Cure Program, the Multiple Myeloma Research Foundation and the RJ Corman Multiple Myeloma Research Fund. CSM and ED are also supported by the Claudia Adams Barr Program in Cancer Research. GMM has been supported by the American Australian Association and the International Myeloma Foundation. MS is supported by the Human Frontier Science Program. Publisher Copyright: © 2016

PY - 2016/8/1

Y1 - 2016/8/1

N2 - The nuclear factor-κB (NF-κB) transcription factor family plays critical roles in the pathophysiology of hematologic neoplasias, including multiple myeloma. The current review examines the roles that this transcription factor system plays in multiple myeloma cells and the nonmalignant accessory cells of the local microenvironment; as well as the evidence indicating that a large proportion of myeloma patients harbor genomic lesions which perturb diverse genes regulating the activity of NF-κB. This article also discusses the therapeutic targeting of the NF-κB pathway using proteasome inhibitors, a pharmacological class that has become a cornerstone in the therapeutic management of myeloma; and reviews some of the future challenges and opportunities for NF-κB-related research in myeloma.

AB - The nuclear factor-κB (NF-κB) transcription factor family plays critical roles in the pathophysiology of hematologic neoplasias, including multiple myeloma. The current review examines the roles that this transcription factor system plays in multiple myeloma cells and the nonmalignant accessory cells of the local microenvironment; as well as the evidence indicating that a large proportion of myeloma patients harbor genomic lesions which perturb diverse genes regulating the activity of NF-κB. This article also discusses the therapeutic targeting of the NF-κB pathway using proteasome inhibitors, a pharmacological class that has become a cornerstone in the therapeutic management of myeloma; and reviews some of the future challenges and opportunities for NF-κB-related research in myeloma.

KW - Microenvironment

KW - Myeloma

KW - NF-kappaB

KW - Proteasome inhibitors

KW - Stromal cells

UR - http://www.scopus.com/inward/record.url?scp=84991268347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991268347&partnerID=8YFLogxK

U2 - 10.1016/j.semcancer.2016.08.005

DO - 10.1016/j.semcancer.2016.08.005

M3 - Review article

C2 - 27544796

AN - SCOPUS:84991268347

SN - 1044-579X

VL - 39

SP - 68

EP - 76

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

ER -

NF-κB dysregulation in multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this